Led by Nigel Minton, Professor of Applied Molecular Microbiology in the Faculty of Medicine and Health Sciences at The University of Nottingham, the research is being presented at the Society for General Microbiology’s Autumn Conference at the University of York.
Professor Minton, from the School of Molecular Medical Sciences, Centre for Biomolecular Sciences, said: “Clostridia are an ancient group of bacteria that evolved on the planet before it had an oxygen-rich atmosphere and so they thrive in low oxygen conditions. When Clostridia spores are injected into a cancer patient, they will only grow in oxygen-depleted environments, i.e. the centre of solid tumours. This is a totally natural phenomenon, which requires no fundamental alterations and is exquisitely specific. We can exploit this specificity to kill tumour cells but leave healthy tissue unscathed.”
The therapy uses Clostridium sporogenes — a bacterium that is widespread in the soil. Spores of the bacterium are injected into patients and only grow in solid tumours, where a specific bacterial enzyme is produced. An anti-cancer drug is injected separately into the patient in an inactive ‘pro-drug’ form. When the pro-drug reaches the site of the tumour, the bacterial enzyme activates the drug, allowing it to destroy only the cells in its vicinity — the tumour cells.
Researchers at The University of Nottingham and the University of Maastricht have now overcome the hurdles that have so far prevented this therapy from entering clinical trials. They have introduced a gene for a much-improved version of the enzyme into the C. sporogenes DNA. The improved enzyme can now be produced in far greater quantities in the tumour than previous versions, and is more efficient at converting the pro-drug into its active form.
A fundamental requirement for any new cancer therapy is the ability to target cancer cells while excluding healthy cells.
The research may ultimately lead to a simple and safe procedure for curing a wide range of solid tumours.
Professor Minton said: “This therapy will kill all types of tumour cell. The treatment is superior to a surgical procedure, especially for patients at high risk or with difficult tumour locations. We anticipate that the strain we have developed will be used in a clinical trial in 2013 led by Jan Theys and Philippe Lambin at the University of Maastricht in The Netherlands. A successful outcome could lead to its adoption as a frontline therapy for treating solid tumours. If the approach is successfully combined with more traditional approaches this could increase our chance of winning the battle against cancerous tumours.”
— Ends —
Notes to editors: The Society for General Microbiology (SGM) is a professional body for scientists who work in all areas of microbiology. It is the largest microbiology society in Europe, and has over 5,000 members worldwide. The Society provides a common meeting ground for scientists working in research and in fields with applications in microbiology including medicine, veterinary medicine, pharmaceuticals, industry, agriculture, food, the environment and education. An important function of the Society is the promotion of the public understanding of microbiology.
The Society for General Microbiology’s Autumn Conference 2011 takes place September 5-7 at the University of York. Full programme details are available on www.sgmyork2011.org.uk.
The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK’s Top 10 and the World’s Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘Europe’s greenest university’ in the UI GreenMetric World University Ranking, a league table of the world’s most environmentally-friendly higher education institutions, which ranked Nottingham second in the world overall.
The University is committed to providing a truly international education for its 40,000 students, producing world-leading research and benefiting the communities around its campuses in the UK and Asia.
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise, with almost 60 per cent of all research defined as ‘world-leading’ or ‘internationally excellent’. Research Fortnight analysis of RAE 2008 ranked the University 7th in the UK by research power.
The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health.
More news from the University at: www.nottingham.ac.uk/news
More information is available from Professor Nigel Minton, at The University of Nottingham, firstname.lastname@example.org or Laura Udakis, at the Society for General Microbiology, +44 (0)118 9881843 or +44 (0) 7990 826696, email@example.com
Lindsay Brooke – Media Relations Manager
Email: firstname.lastname@example.org Phone: +44 (0)115 951 5751 Location: King’s Meadow Campus